Database : MEDLINE
Search on : asthma [Words]
References found : 158148 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 15815 go to page                         

  1 / 158148 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524924
[Au] Autor:Han C; Hong YC
[Ad] Address:Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
[Ti] Title:Adverse health effects of ferronickel manufacturing factory on local residents: An interrupted time series analysis.
[So] Source:Environ Int;114:288-296, 2018 Mar 07.
[Is] ISSN:1873-6750
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:The first ferronickel manufacturing factory of the Republic of Korea was opened in Gwangyang City on October, 23rd, 2008. There has been public concern regarding heavy metal dust blown from the factory and slag disposal site. Therefore, we evaluated the health impact of the ferronickel factory on Gwangyang City residents by using interrupted time series analysis. We analyzed the monthly incidence patterns of asthma, allergic rhinitis, and dermatitis in Gwangyang City residents from 2004 to 2014. Data were gathered from the National Health Insurance Service database which covers all the hospital use data of entire city residents. Seasonality adjusted quasi-Poisson regression model was used to evaluate whether the operation of the ferronickel factory was associated with the immediate changes in the monthly disease incidence patterns. We set a control region, Yeosu City, near Gwangyang City to ensure that the changes in the disease incidence were specific to Gwangyang City. We conducted sub-regional level analysis to evaluate whether the disease incidence patterns were affected by the distance from the ferronickel factory. The risk estimates after operation of the ferronickel factory showed an abrupt increase in the monthly incidence of unspecified dermatitis [RR (95% CI), 1.75 (1.17-2.60)] and vasomotor and allergic rhinitis [RR (95% CI), 1.23 (1.08-1.39)] in men, and pruritus [RR (95% CI), 1.95 (1.51-2.52)], unspecified dermatitis [RR (95% CI), 1.65 (1.04-2.60)], and vasomotor and allergic rhinitis [RR (95% CI), 1.17 (1.04-1.31)] in women. These findings were significant even after accounting for the changes of the corresponding disease incidence of the comparison city, Yeosu. The effects were greater in young children (aged 0-9) and sub-regions near the ferronickel factory. Our study suggests possible association between the operation of the ferronickel factory and an abrupt increase of pruritus, unspecific dermatitis, and vasomotor and allergic rhinitis in Gwangyang City residents.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524559
[Au] Autor:Greenhawt M; Chan ES; Fleischer DM; Hicks A; Wilson R; Shaker M; Venter C; Stukus D
[Ad] Address:Children's Hospital Colorado, University of Colorado School of Medicine, Section of Allergy and Immunology, Aurora, CO. Electronic address: Matthew.Greenhawt@childrenscolorado.org.
[Ti] Title:Caregiver and expecting caregiver support for early peanut introduction guidelines.
[So] Source:Ann Allergy Asthma Immunol;, 2018 Mar 07.
[Is] ISSN:1534-4436
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Recent guidelines recommend early peanut introduction (EPI) beginning around 4-6 months in infants with either severe eczema and/or egg allergy, and around 6 months for all other infants. Caregiver preferences for such practices are unkown. METHODS: We explored preferences for EPI and in-office allergy risk assessment (IRA) through a nationally-representative survey of expecting (n=1000) and new caregivers of infants < 1 year (n=1000). RESULTS: Among a primarily female (99.7%), married (80.3%), and white (74.4%) sample, 29% had no/vague awareness of the new guidelines, 61% had no/minimal concern for their child developing food allergy, but 54% felt timing of introduction has moderate/strong importance for developing food allergy. Only 31% expressed willingness for EPI before/around 6 months of life, with 40% reporting willingness to introduce peanut after 11 months of life, similar to tree nuts and seafood. However, 60% reported willingness to introduce egg before 8 months. 51% and 56.8% were unwilling to allow IRA methods such as skin testing and oral challenge before 11 months of life, respectively. Odds of willingness to both delay peanut introduction and undergo challenge after 6 months of life were lower among expecting caregivers (OR 0.79, CI 0.65-0.96; OR 0.67, CI 0.54-0.82, respectively). CONCLUSIONS: Among new and expecting caregivers, there is poor current willingness and questionable support for early allergenic solid food recommendations, including IRA before introduction. Willingness was better among expecting versus current caregivers. These trends underscore a need for broader formal implementation planning to facilitate early allergen introduction and maximize its preventive benefits.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  3 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524537
[Au] Autor:Peters MC; Kerr S; Dunican EM; Woodruff PG; Fajt ML; Levy BD; Israel E; Phillips BR; Mauger DT; Comhair SA; Erzurum SC; Johansson MW; Jarjour NN; Coverstone AM; Castro M; Hastie AT; Bleecker ER; Wenzel SE; Fahy JV; National Heart Lung and Blood Institute Severe Asthma Research Program-3
[Ad] Address:Division of Pulmonary and Critical Care Medicine, Department of Medicine and the Cardiovascular Research Institute, University of California San Francisco. 505 Parnassus Avenue, San Francisco, CA 94143-0130.
[Ti] Title:Refractory Airway Type-2 Inflammation in a Large Subgroup of Asthmatics treated with Inhaled Corticosteroids.
[So] Source:J Allergy Clin Immunol;, 2018 Mar 07.
[Is] ISSN:1097-6825
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Airway type 2 inflammation is usually corticosteroid sensitive, but the role of type 2 inflammation as a mechanism of asthma in patients on high dose inhaled corticosteroids (ICS) is uncertain. OBJECTIVE: To determine if airway type 2 inflammation persists in patients treated with ICS and to evaluate the clinical features of patients with steroid resistant airway type-2 inflammation. METHODS: We used qPCR to generate a composite metric of type-2 cytokine gene expression (type 2 Gene Mean, "T2GM") in induced sputum cells from healthy controls, severe asthma patients on ICS (n=174), and non-severe asthma patients on ICS (n=85). We explored relationships between asthma outcomes and the T2GM, and the utility of non-invasive biomarkers of the airway T2GM. RESULTS: The sputum cell T2GM in asthma subjects was significantly increased in asthma subjects and remained high following treatment with intramuscular triamcinolone. We used the median value for the T2GM as a cutoff to classify "steroid-treated type 2-low" (stT2-low) and "steroid-resistant type 2-high" (srT2-high) subgroups. Compared to patients with stT2-low asthma, those with srT2-high asthma were older age and had more severe asthma. Blood eosinophil cell counts predicted srT2-high asthma when BMI was < 40, but not when it was ≥40, whereas, blood IgE strongly predicted srT2-high asthma when age was < 34 years but not when it was ≥34. CONCLUSION: Despite ICS therapy many asthmatics have persistent airway type 2 inflammation, (srT2-high asthma) and these patients are older and have more severe disease. Body weight and age modify the performance of blood-based biomarkers of airway type-2 inflammation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  4 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524536
[Au] Autor:Morten M; Collison A; Murphy VE; Barker D; Oldmeadow C; Attia J; Meredith J; Powell H; Robinson PD; Sly PD; Gibson PG; Mattes J
[Ad] Address:Priority Research Centre GrowUpWell®, Hunter Medical Research Institute and University of Newcastle, NSW, Australia, 2305; Hunter Medical Research Institute, Newcastle, NSW, Australia 2305 and School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia, 2308.
[Ti] Title:Managing Asthma in Pregnancy (MAP) trial: FeNO levels and childhood asthma.
[So] Source:J Allergy Clin Immunol;, 2018 Mar 07.
[Is] ISSN:1097-6825
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The single-centre double-blind, randomised controlled Managing Asthma in Pregnancy (MAP) trial in Newcastle, Australia, compared a treatment algorithm using the fraction of exhaled nitric oxide (FeNO) in combination with asthma symptoms (FeNO group) against a treatment algorithm using clinical symptoms only (clinical group) in pregnant asthmatic women (ANZ Clinical Trials Registry, number 12607000561482). The primary outcome was a 50% reduction in asthma exacerbations during pregnancy in the FeNO group. However, the effect of FeNO-guided management on the development of asthma in the offspring is unknown. OBJECTIVE: We sought to investigate the effect of FeNO-guided asthma management during pregnancy on asthma incidence in childhood. METHODS: 179 mothers consented to participate in the Growing Into Asthma (GIA) double-blind follow-up study with the primary aim to determine the effect of FeNO-guided asthma management on childhood asthma incidence. RESULTS: 140 children (78%) were followed up at 4 to 6 years of age. FeNO-guided as compared to symptoms only based approach significantly reduced doctor diagnosed asthma (25·9% versus 43·2%; odds ratio [OR] 0.46, 95% confidence interval [CI] 0.22 to 0.96, p=0.04). Furthermore frequent wheeze (OR 0.27; CI 0.09 to 0.87, p=0.03), use of short-acting beta agonists (OR 0.49; CI 0.25 to 0.97; p=0.04), and emergency department visits for asthma (OR 0.17, CI 0.04 to 0.76; p=0.02) in the past 12 months were less common in children born to mothers from the FeNO group. Doctor diagnosed asthma was associated with common risk alleles for early-onset asthma at gene locus 17q21 (p=0·01 for rs8069176; p=0·03 for rs8076131), and higher airways resistance (p=0·02) and FeNO levels (p=0·03). A causal mediation analysis suggested natural indirect effects of FeNO-guided asthma management on childhood asthma through "any use" and "time to first change in dose" of inhaled corticosteroids during the MAP trial (OR 0.83; CI 0.59 to 0.99 and OR 0.90, CI 0.70 to 1.03, respectively). CONCLUSION: FeNO-guided asthma management during pregnancy prevented doctor diagnosed asthma in the offspring at preschool age, in part mediated through changes in use and dosing of inhaled corticosteroids during the MAP trial.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  5 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524387
[Au] Autor:Anzueto A; Miravitlles M
[Ad] Address:Pulmonary/Critical Care, University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX. Electronic address: anzueto@uthscsa.edu.
[Ti] Title:Considerations for the Correct Diagnosis of Chronic Obstructive Pulmonary Disease and Its Management With Bronchodilators.
[So] Source:Chest;, 2018 Mar 07.
[Is] ISSN:1931-3543
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Chronic obstructive pulmonary disease (COPD) is often misdiagnosed and inappropriately treated in many patients. COPD is a distinct disease from adult-onset asthma; however, some patients with COPD may present with several forms of airway disease described as asthma-COPD overlap (ACO). Bronchodilators and inhaled corticosteroids (ICS) both have a place in standard maintenance treatment of COPD and asthma; however, recommendations for use differ widely. In patients with COPD, long-acting bronchodilators are effective initial monotherapy treatment, while ICS monotherapy is recommended as initial treatment in patients with asthma. Clinicians need to be confident in their diagnosis to ensure that correct treatment is given, as misguided treatment decisions can result in significantly increased safety risks for patients. This review highlights the differences in diagnosis and treatment between COPD, asthma, and ACO and discusses the data supporting guideline recommendations for use of bronchodilators in COPD treatment in contrast to asthma or ACO.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  6 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29520136
[Au] Autor:Savran O; Ulrik CS
[Ad] Address:Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark.
[Ti] Title:Early life insults as determinants of chronic obstructive pulmonary disease in adult life.
[So] Source:Int J Chron Obstruct Pulmon Dis;13:683-693, 2018.
[Is] ISSN:1178-2005
[Cp] Country of publication:New Zealand
[La] Language:eng
[Ab] Abstract:Background: Early life events may predispose to the development of chronic lung disease in adulthood. Aim: To provide an update on current knowledge of early nongenetic origins of COPD. Materials and methods: Systematic literature review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: A total of 16 studies, comprising 69,365 individuals, met the predefined criteria and were included in the present review. Studies have shown that in utero tobacco exposure, low birth weight, preterm birth, and respiratory diseases, primarily asthma and pneumonia, in early childhood are associated with lung function impairment later in childhood, and by that predispose to subsequent development of COPD, although the causal association between childhood respiratory diseases and COPD has been questioned in one study. Environmental tobacco exposure has also been shown to have negative impact on lung function in childhood possibly leading to COPD in adulthood, although it is at present not possible to clearly distinguish between the impact of active and the environmental tobacco exposure on subsequent development of COPD. Conclusion: Tobacco exposure in utero and early life is a risk factor for subsequent development of COPD. Furthermore, low birth weight, lower respiratory tract infections and asthma, including wheezy bronchitis, in childhood also seem to be important determinants for later development of COPD. Early life insults may, therefore, be crucial to COPD development.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.2147/COPD.S153555

  7 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29511677
[Au] Autor:Lew DB; LeMessurier KS; Palipane M; Lin Y; Samarasinghe AE
[Ad] Address:Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
[Ti] Title:-Derived Mannan Does Not Alter Immune Responses to Allergens.
[So] Source:Biomed Res Int;2018:3298378, 2018.
[Is] ISSN:2314-6141
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Severe asthma with fungal sensitization predominates in the population suffering from allergic asthma, to which there is no cure. While corticosteroids are the mainstay in current treatment, other means of controlling inflammation may be beneficial. Herein, we hypothesized that mannan from would dampen the characteristics of fungal allergic asthma by altering the pulmonary immune responses. Using wild-type and transgenic mice expressing the human mannose receptor on smooth muscle cells, we explored the outcome of mannan administration during allergen exposure on the pathogenesis of fungal asthma through measurement of cardinal features of disease such as inflammation, goblet cell number, and airway hyperresponsiveness. Mannan treatment did not alter most hallmarks of allergic airways disease in wild-type mice. Transgenic mice treated with mannan during allergen exposure had an equivalent response to non-mannan-treated allergic mice except for a prominent granulocytic influx into airways and cytokine availability. Our studies suggest no role for mannan as an inflammatory regulator during fungal allergy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Process
[do] DOI:10.1155/2018/3298378

  8 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29474935
[Au] Autor:Bengtsson T; Román J; Persson T
[Ad] Address:Statmind Statistical and Mathematical Modelling, Innovation and Design AB, Lund, Sweden. Electronic address: thomas.bengtsson@statmind.se.
[Ti] Title:The use of methacholine provocation when assessing therapeutic equivalence between two inhalers in asthmatic patients.
[So] Source:Contemp Clin Trials;67:87-90, 2018 Feb 21.
[Is] ISSN:1559-2030
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:A planned change from Bricanyl® (terbutaline) Turbuhaler® M2 to M3 device required a pharmacodynamic study to evaluate therapeutic equivalence of the two devices. Because of the flat dose-response curve for this type of agent over this dose range when assessing bronchodilation, a bronchoprotection study was considered more feasible. In this double-blind, double-dummy, multicentre, single-dose, two-factor, crossover study, patients with stable mild-to-moderate asthma were randomised to 0.5 or 1.5 mg terbutaline via Turbuhaler® M2 or Turbuhaler® M3 followed by a methacholine challenge test. Primary outcome variable: concentration of methacholine causing a 20% fall in FEV (PC ). Pairwise contrasts were constructed with 95% CIs to determine assay sensitivity for M2 and M3 devices and therapeutic equivalence at each dose level (95% CI for M3:M2 devices within pre-specified limit [0.67-1.50]) and the relative dose-potency (RDP) between M3 and M2 determined with 90% CI. Sixty patients were randomised and all completed the study. Between-device ratios of PC (M3:M2) were 0.92 (95% CI: 0.75-1.13) for 0.5 mg and 0.88 (95% CI 0.72-1.08) for 1.5 mg and estimated RDP was 1.20 (0.96-1.53). In conclusion, a methacholine provocation study (PC primary variable) is a useful alternative to the standard bronchodilation study when assessing therapeutic equivalence of a bronchodilator.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  9 / 158148 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29432856
[Au] Autor:Azevedo BC; Morel LJF; Carmona F; Cunha TM; Contini SHT; Delprete PG; Ramalho FS; Crevelin E; Bertoni BW; França SC; Borges MC; Pereira AMS
[Ad] Address:Departamento de Biotecnologia em Plantas Medicinais, Universidade de Ribeirão Preto, Av. Costábile Romano 2201, 14096-900 Ribeirão Preto, SP, Brazil.
[Ti] Title:Aqueous extracts from Uncaria tomentosa (Willd. ex Schult.) DC. reduce bronchial hyperresponsiveness and inflammation in a murine model of asthma.
[So] Source:J Ethnopharmacol;218:76-89, 2018 Feb 10.
[Is] ISSN:1872-7573
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Uncaria tomentosa (Willd. Ex Schult) DC is used by indigenous tribes in the Amazonian region of Central and South America to treat inflammation, allergies and asthma. The therapeutic properties of U. tomentosa have been attributed to the presence of tetracyclic and pentacyclic oxindole alkaloids and to phenolic acids. AIMS OF THE STUDY: To characterize aqueous bark extracts (ABE) and aqueous leaf extracts (ALE) of U. tomentosa and to compare their anti-inflammatory effects. MATERIALS AND METHODS: Constituents of the extracts were identified by ultra performance liquid chromatography-mass spectrometry. Anti-inflammatory activities were assessed in vitro by exposing lipopolysaccharide-stimulated macrophage cells (RAW264.7-Luc) to ABE, ALE and standard mitraphylline. In vivo assays were performed using a murine model of ovalbumin (OVA)-induced asthma. OVA-sensitized animals were treated with ABE or ALE while controls received dexamethasone or saline solution. Bronchial hyperresponsiveness, production of Th1 and Th2 cytokines, total and differential counts of inflammatory cells in the bronchoalveolar lavage (BAL) and lung tissue were determined. RESULTS: Mitraphylline, isomitraphylline, chlorogenic acid and quinic acid were detected in both extracts, while isorhyncophylline and rutin were detected only in ALE. ABE, ALE and mitraphylline inhibited the transcription of nuclear factor kappa-B in cell cultures, ALE and mitraphylline reduced the production of interleukin (IL)-6, and mitraphylline reduced production of tumor necrosis factor-alpha. Treatment with ABE and ALE at 50 and 200 mg kg , respectively, reduced respiratory elastance and tissue damping and elastance. ABE and ALE reduced the number of eosinophils in BAL, while ALE at 200 mg kg reduced the levels of IL-4 and IL-5 in the lung homogenate. Peribronchial inflammation was significantly reduced by treatment with ABE and ALE at 50 and 100 mg kg respectively. CONCLUSION: The results clarify for the first time the anti-inflammatory activity of U. tomentosa in a murine model of asthma. Although ABE and ALE exhibited distinct chemical compositions, both extracts inhibited the production of pro-inflammatory cytokines in vitro. In vivo assays revealed that ABE was more effective in treating asthmatic inflammation while ALE was more successful in controlling respiratory mechanics. Both extracts may have promising applications in the phytotherapy of allergic asthma.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  10 / 158148 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29374573
[Au] Autor:Kothari PH; Qiu W; Croteau-Chonka DC; Martinez FD; Liu AH; Lemanske RF; Ober C; Krishnan JA; Nicolae DL; Barnes KC; London SJ; Barraza-Villarreal A; White SR; Naureckas ET; Millstein J; Gauderman WJ; Gilliland FD; Carey VJ; Weiss ST; Raby BA; Asthma BioRepository for Integrative Genomic Exploration (Asthma BRIDGE) Consortium
[Ad] Address:Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. Electronic address: r
[Ti] Title:Role of local CpG DNA methylation in mediating the 17q21 asthma susceptibility gasdermin B (GSDMB)/ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) expression quantitative trait locus.
[So] Source:J Allergy Clin Immunol;, 2018 Jan 31.
[Is] ISSN:1097-6825
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:Publisher


page 1 of 15815 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information